Literature DB >> 33732560

T-cell Prolymphocytic Leukemia, Cerebriform Variant.

José Carvalho1, Alexandra Esteves1, Francisco Teixeira da Silva1, Joana Couto1, Carlos Ribeiro1.   

Abstract

T-cell prolymphocytic leukemia (T-PLL) is a very rare and aggressive lymphoproliferative disorder. We present a 70-year-old man with complaints of fatigue, low urinary output, and peripheral edema for one month. Objectively, he presented diminished respiratory sounds bilaterally and peripheral edema. Analytical study revealed mild anemia and mild lymphomonocytosis, acute kidney injury, and urinalysis with proteins, leukocytes, erythrocytes, and cylinders. Chest radiography was consistent with pleural effusion. Subsequent study showed new onset of thrombocytopenia with a progressive increase of lymphocytosis, in association with inguinal adenopathies and splenomegaly. Immunophenotypic study of peripheral blood and lymph node biopsy were compatible with the diagnosis of T-PLL. Negative serology for human T-cell lymphotropic virus type 1 (HTLV-1) excluded adult T-cell leukemia. Progressive changes in the peripheral blood smear were seen, finally showing the presence of lymphocytes with a cerebriform nucleus, revealing this variant. There was a rapid catastrophic progression, spontaneous tumor lysis syndrome, and death.
Copyright © 2021, Carvalho et al.

Entities:  

Keywords:  adenopathy; cerebriform; lymphocytosis; splenomegaly; t-cell leukemia

Year:  2021        PMID: 33732560      PMCID: PMC7956018          DOI: 10.7759/cureus.13299

Source DB:  PubMed          Journal:  Cureus        ISSN: 2168-8184


  6 in total

Review 1.  Consensus criteria for diagnosis, staging, and treatment response assessment of T-cell prolymphocytic leukemia.

Authors:  Philipp B Staber; Marco Herling; Mar Bellido; Eric D Jacobsen; Matthew S Davids; Tapan Mahendra Kadia; Andrei Shustov; Olivier Tournilhac; Emmanuel Bachy; Francesco Zaja; Kimmo Porkka; Gregor Hoermann; Ingrid Simonitsch-Klupp; Claudia Haferlach; Stefan Kubicek; Marius E Mayerhoefer; Georg Hopfinger; Ulrich Jaeger; Claire Dearden
Journal:  Blood       Date:  2019-07-10       Impact factor: 22.113

2.  T-cell prolymphocytic leukemia.

Authors:  Robbie L Graham; Barry Cooper; John R Krause
Journal:  Proc (Bayl Univ Med Cent)       Date:  2013-01

Review 3.  The tumor lysis syndrome.

Authors:  Scott C Howard; Deborah P Jones; Ching-Hon Pui
Journal:  N Engl J Med       Date:  2011-05-12       Impact factor: 91.245

4.  Comparison of clinicopathological characteristics between T-cell prolymphocytic leukemia and peripheral T-cell lymphoma, not otherwise specified.

Authors:  Keisuke Kawamoto; Hiroaki Miyoshi; Eriko Yanagida; Noriaki Yoshida; Junichi Kiyasu; Yasuji Kozai; Tatsuma Morikita; Takeharu Kato; Hitoshi Suzushima; Shinobu Tamura; Tsuyoshi Muta; Koji Kato; Tetsuya Eto; Ritsuko Seki; Koji Nagafuji; Hirohito Sone; Jun Takizawa; Masao Seto; Koichi Ohshima
Journal:  Eur J Haematol       Date:  2017-03-03       Impact factor: 2.997

5.  Advances and Perspectives in the Treatment of T-PLL.

Authors:  Till Braun; Jana von Jan; Linus Wahnschaffe; Marco Herling
Journal:  Curr Hematol Malig Rep       Date:  2020-04       Impact factor: 3.952

6.  Characteristics, outcomes, prognostic factors and treatment of patients with T-cell prolymphocytic leukemia (T-PLL).

Authors:  P Jain; E Aoki; M Keating; W G Wierda; S O'Brien; G N Gonzalez; A Ferrajoli; N Jain; P A Thompson; E Jabbour; R Kanagal-Shamanna; S Pierce; A Alousi; C Hosing; I Khouri; Z Estrov; J Cortes; H Kantarjian; F Ravandi; T M Kadia
Journal:  Ann Oncol       Date:  2017-07-01       Impact factor: 32.976

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.